Menactra

Menactra
Name	Menactra
Type	conjugate vaccine
Target	Neisseria meningitidis serogroups A, C, W, Y
Developer	Sanofi Pasteur
Route	intramuscular
Approved	2005 (United States)

Menactra is a quadrivalent meningococcal conjugate vaccine indicated to prevent invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y. It is produced by Sanofi Pasteur and has been used in routine adolescent immunization programs and outbreak control efforts in multiple countries, often alongside other public health measures from agencies such as the Centers for Disease Control and Prevention and the World Health Organization. The vaccine has been evaluated in randomized controlled trials, cohort studies, and post-marketing surveillance that informed recommendations by advisory bodies including the Advisory Committee on Immunization Practices and national immunization technical advisory groups in countries such as the United States, Canada, and members of the European Union.

Medical uses

Menactra is indicated for active immunization against invasive meningococcal disease caused by the targeted serogroups in persons at increased risk, including adolescents, travelers to endemic regions, and individuals with certain immunocompromising conditions. Recommendations for use have been integrated into adolescent immunization schedules promulgated by organizations such as the American Academy of Pediatrics, the Infectious Diseases Society of America, and the Public Health Agency of Canada. Outbreak response protocols from the World Health Organization and national ministries of health have included use of conjugate meningococcal vaccines in mass vaccination campaigns in settings such as the African meningitis belt and during university campus outbreaks in the United States and United Kingdom. Immunization strategies consider risk groups identified by entities like the Department of Defense for military recruits and by public health agencies for laboratory personnel working with Neisseria meningitidis.

Composition and mechanism of action

The vaccine consists of capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y individually conjugated to the diphtheria toxoid protein CRM197, a non-toxic mutant of diphtheria toxin used in other formulations such as the Haemophilus influenzae type b conjugate vaccines and certain pneumococcal conjugate vaccines. Conjugation to CRM197 converts T-cell independent polysaccharide antigens into T-cell dependent forms, enhancing immunogenicity in adolescents and younger recipients by eliciting memory B-cell responses and class-switched, high-affinity antibodies. The vaccine stimulates production of bactericidal antibodies measured by assays endorsed by reference laboratories like the National Institute for Biological Standards and Control and research centers affiliated with the National Institutes of Health and university departments of infectious disease and immunology.

Administration and dosing

Menactra is administered by intramuscular injection, typically in the deltoid region, by healthcare providers in clinical settings such as primary care clinics, student health centers, and military medical facilities. Standard dosing recommendations from the Advisory Committee on Immunization Practices advise a single dose for adolescents with a booster dose for certain populations, while specific schedules for younger children, travelers, and immunocompromised patients are informed by national guidelines from bodies such as the European Centre for Disease Prevention and Control and the Public Health Agency of Canada. Co-administration considerations with other vaccines used in adolescent programs—such as the human papillomavirus vaccine, Tdap vaccine, and influenza vaccine—have been evaluated in clinical studies and incorporated into practice guidance by professional societies including the American Academy of Family Physicians.

Efficacy and safety

Clinical trials funded by manufacturers and conducted at academic centers and public health institutions demonstrated that Menactra induces serum bactericidal antibody responses against the included serogroups, with effectiveness estimates derived from immunogenicity bridging and field studies. Post-licensure effectiveness studies during outbreaks and routine programmatic use, reported through surveillance systems like the Vaccine Adverse Event Reporting System and national notifiable disease registries, have supported real-world protective impact against invasive meningococcal disease in vaccinated cohorts. Safety assessments in randomized trials and observational studies were reviewed by regulatory agencies such as the Food and Drug Administration and the European Medicines Agency, with continuous monitoring by pharmacovigilance programs coordinated with institutions like the Centers for Disease Control and Prevention.

Adverse effects and contraindications

Common adverse reactions reported in clinical trials and surveillance include injection-site pain, erythema, and swelling, as well as systemic events such as fever, headache, and malaise; these findings were summarized in product information reviewed by regulators including the Food and Drug Administration. Rare but serious events, monitored through passive and active surveillance systems involving agencies like the Vaccine Safety Datalink and national pharmacovigilance centers, have been evaluated for causality though definitive associations are uncommon. Contraindications typically include a history of severe allergic reaction to a previous dose or to a vaccine component such as diphtheria toxoid derivatives; guidance for vaccination in individuals with Guillain–Barré syndrome or other neurologic conditions has been provided by professional bodies such as the Advisory Committee on Immunization Practices and specialty societies.

Regulatory history and availability

Menactra received regulatory approval in the United States in 2005 after review by the Food and Drug Administration, followed by licensing and recommendations in other jurisdictions including Canada and several European Union member states through respective national competent authorities and the European Medicines Agency regulatory framework. Manufacturing, labeling, and distribution have been overseen by Sanofi Pasteur with post-marketing commitments to regulatory agencies for safety monitoring. Availability varies by country and is influenced by national immunization schedules, procurement by ministries of health, and use in outbreak response coordinated with partners such as the World Health Organization and regional public health institutions.

Category:Meningococcal vaccines